Related Experiment Video

Updated: Aug 15, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Pediatric implications of heterozygous familial hypercholesterolemia. Screening and dietary treatment

P O Kwiterovich1

  • 1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Arteriosclerosis (Dallas, Tex.)
|January 1, 1989
PubMed

Insights

Early detection and treatment of heterozygous familial hypercholesterolemia (FH) in children is crucial. Lifestyle changes and medication can effectively lower LDL cholesterol levels, preventing premature heart disease.

Area of Science:

  • Pediatric Endocrinology
  • Cardiovascular Genetics
  • Nutritional Science

Background:

  • Familial hypercholesterolemia (FH) presents with significantly elevated LDL cholesterol from birth.
  • Low HDL cholesterol levels can also be observed in FH patients.
  • Current LDL cholesterol screening is effective in families with known FH but lacks specificity for general populations.

Purpose of the Study:

  • To evaluate the effectiveness of early detection and management of heterozygous FH in children.
  • To explore the impact of dietary interventions on cholesterol levels in pediatric FH.
  • To highlight the importance of timely treatment for preventing early coronary artery disease.

Main Methods:

  • Review of current screening methods for FH in children.
  • Analysis of dietary recommendations for FH management.
  • Assessment of the role of pharmacologic interventions in conjunction with lifestyle changes.

Main Results:

  • Dietary modifications (low cholesterol, fat, saturated fat; enriched polyunsaturated fat) can reduce LDL cholesterol by 10-15% in children with FH.
  • Many children with FH will require medication to achieve optimal LDL cholesterol reduction.
  • Early detection and intervention are key to managing FH.

Conclusions:

  • Prompt diagnosis and treatment of FH in childhood are essential for cardiovascular health.
  • A combination of diet and medication provides the most effective strategy for lowering LDL cholesterol.
  • Aggressive management of FH in pediatric patients can prevent premature coronary artery disease.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Assessing Whole-Body Lipid-Handling Capacity in Mice07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...